Cargando…

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights

BACKGROUND: Siponimod (BAF312), a selective S1P(1)/S1P(5) agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could act via S1P(1)/S1P(5)-dependent anti-inflammatory and pro-myelination effects on CNS-resident cells. OBJECTIVE: Generate preclinical evi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bigaud, Marc, Rudolph, Bettina, Briard, Emmanuelle, Beerli, Christian, Hofmann, Andreas, Hermes, Erwin, Muellershausen, Florian, Schubart, Anna, Gardin, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573504/ https://www.ncbi.nlm.nih.gov/pubmed/34777855 http://dx.doi.org/10.1177/20552173211049168

Ejemplares similares

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
por: O’Sullivan, Catherine, et al.
Publicado: (2016)

The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis
por: Hundehege, Petra, et al.
Publicado: (2019)

Lymphocyte-Related Immunomodulatory Therapy with Siponimod (BAF-312) Improves Outcomes in Mice with Acute Intracerebral Hemorrhage
por: Zhang, Zhiying, et al.
Publicado: (2023)

Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration
por: Colombo, Emanuela, et al.
Publicado: (2020)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
por: Bigaud, Marc, et al.
Publicado: (2023)

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis
por: Weier, Alicia, et al.
Publicado: (2022)

Microglia Contributes to BAF-312 Effects on Blood–Brain Barrier Stability
por: Spampinato, Simona Federica, et al.
Publicado: (2022)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
por: Gergely, P, et al.
Publicado: (2012)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

Siponimod for multiple sclerosis
Publicado: (2021)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Decreased Astrocytic CCL2 Accounts for BAF-312 Effect on PBMCs Transendothelial Migration Through a Blood Brain Barrier in Vitro Model
por: Spampinato, Simona F., et al.
Publicado: (2021)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Errata in No. 312
Publicado: (1825)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
por: Huth, Felix, et al.
Publicado: (2019)

The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P(1)) and Hypertension (S1P(3)) in Rat
por: Fryer, Ryan M., et al.
Publicado: (2012)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Retinal Electrophysiology Is a Viable Preclinical Biomarker for Drug Penetrance into the Central Nervous System
por: Charng, Jason, et al.
Publicado: (2016)

BAF goes nuclear
por: Dove, Alan W.
Publicado: (2002)

Multifunctional BAF-1
por: Williams, Ruth
Publicado: (2007)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma
por: Gong, Ke, et al.
Publicado: (2020)

The BAF complex and HIV latency
por: Mahmoudi, Tokameh
Publicado: (2012)

The BAF complex in development and disease
por: Alfert, Amelie, et al.
Publicado: (2019)

Role of BAF60a/BAF60c in chromatin remodeling and hepatic lipid metabolism
por: Zhang, Ping, et al.
Publicado: (2016)

Health Tract No. 312: Early Rising
Publicado: (1868)

Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer
por: Gong, Ke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hefuvu1rauj2nsbdqsheiglhr